Inspire Pharmaceuticals have announced modifications to the clinical protocol for TIGER-2, the Company’s ongoing second Phase 3 trial with denufosol tetrasodium for the treatment of cystic fibrosis (CF).
Filed under: gpcr | Tagged: agonist, denufosol, INS-37217, INS37217, Inspire, P2Y2, Purinoreceptor, Purinoreceptor P2Y2 | Leave a Comment »
